Can I Take Omega-3 (EPA/DHA) with Evenity (Romosozumab)?

What Is Romosozumab (Evenity) and Why Does the Cardiovascular Warning Matter?

Romosozumab is a monoclonal antibody that blocks sclerostin, a protein produced by osteocytes that normally inhibits bone formation. Blocking sclerostin produces a dual effect: it simultaneously increases bone formation markers and decreases bone resorption markers. The FRAME trial (N=7,180) showed that 12 months of romosozumab 210 mg monthly reduced new vertebral fracture risk by 73% versus placebo in postmenopausal women with osteoporosis [1].

That benefit comes with a notable safety footnote. The FDA-approved Evenity label carries a boxed warning stating that the drug should not be started in patients who have experienced a myocardial infarction (MI) or stroke within the preceding 12 months [2]. The ARCH trial (N=4,093) compared romosozumab followed by alendronate against alendronate alone and found a higher rate of serious cardiovascular events in the romosozumab arm (2.5% vs. 1.9%, P<0.05) [3].

Why This Warning Shapes Every Supplement Conversation

Patients eligible for Evenity are predominantly postmenopausal women over 65. This demographic has a background prevalence of hypertension, dyslipidemia, and prior cardiovascular events that is meaningfully higher than the general population. Any co-administered supplement or drug that modulates platelet function, blood pressure, or lipid metabolism deserves explicit review in this context.

Omega-3 fatty acids sit squarely in that category. They are among the most widely used supplements in the United States. The National Institutes of Health Office of Dietary Supplements reports that approximately 19 million U.S. Adults use fish oil supplements [4]. Many of these adults are in the exact age group prescribed romosozumab.

Romosozumab Mechanism in Brief

Romosozumab binds sclerostin with high affinity (Kd approximately 0.1 nM). Sclerostin is encoded by the SOST gene and acts as a Wnt signaling inhibitor at the osteoblast surface. Neutralizing sclerostin releases Wnt-mediated bone formation. Bone-specific alkaline phosphatase (a formation marker) rises within the first month of treatment, while C-terminal telopeptide (a resorption marker) falls. This dual mechanism distinguishes romosozumab from pure anabolic agents (teriparatide) and pure antiresorptives (bisphosphonates).

How Do Omega-3 Fatty Acids (EPA and DHA) Work?

Omega-3 fatty acids are long-chain polyunsaturated fats. Eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3) are the two biologically active marine-derived forms found in fish oil capsules and prescription formulations like icosapentaenoic acid ethyl ester (Vascepa) and omega-3 acid ethyl esters (Lovaza).

Lipid Effects

At prescription doses of 4 g/day, marine omega-3s reduce triglycerides by 20 to 30% [5]. The REDUCE-IT trial (N=8,179) demonstrated that icosapentaenoic acid ethyl esters 4 g/day reduced major adverse cardiovascular events by 25% relative to placebo in patients with elevated triglycerides already on a statin [6]. Standard OTC supplemental doses (1 to 2 g combined EPA+DHA daily) produce more modest triglyceride reductions of 5 to 10% and do not replicate the REDUCE-IT cardiovascular benefit.

Romosozumab has no known direct effect on triglycerides. The combination therefore does not create a synergistic triglyceride-lowering risk; if anything, modest TG reduction might be neutral-to-favorable in patients with metabolic comorbidities.

Antiplatelet and Hemostatic Effects

This is the more clinically relevant pharmacodynamic concern. EPA and DHA compete with arachidonic acid for cyclooxygenase (COX) and lipoxygenase enzymes, partially reducing thromboxane A2 synthesis. Thromboxane A2 is a potent platelet activator. A meta-analysis published in the Journal of the American Heart Association (N=10 RCTs, 1,788 participants) found that omega-3 supplementation prolonged bleeding time and reduced platelet aggregation in a dose-dependent manner, with effects becoming more pronounced above 3 g/day EPA+DHA [7].

Romosozumab itself is not an anticoagulant and does not directly affect platelet function. However, the cardiovascular event signal in ARCH raises the question of whether additional platelet modification in a high-risk patient could tip hemostatic balance.

Bone Effects of Omega-3s

A secondary consideration that is often overlooked: omega-3 fatty acids may independently support bone mineral density (BMD). A meta-analysis in Osteoporosis International (N=14 RCTs) found that EPA+DHA supplementation was associated with a small but statistically significant increase in lumbar spine BMD (weighted mean difference +0.02 g/cm², P<0.05) compared to control [8]. This suggests that omega-3s and romosozumab could share a directionally aligned effect on bone, which is pharmacologically favorable rather than concerning.

Is This Interaction Pharmacokinetic or Pharmacodynamic?

The distinction matters clinically. Pharmacokinetic interactions change how a drug is absorbed, distributed, metabolized, or excreted. Pharmacodynamic interactions change what a drug does at the tissue level, without altering its concentration in blood.

Pharmacokinetic Profile of Romosozumab

Romosozumab is a large-molecule monoclonal antibody (approximately 150 kDa). Large biologics are not metabolized by cytochrome P450 (CYP) enzymes in the liver. They are catabolized via endosomal degradation pathways into amino acids and small peptides, the same route used to break down any endogenous immunoglobulin. Because omega-3 fatty acids are also not CYP substrates in the conventional drug-interaction sense, there is no pharmacokinetic mechanism by which EPA or DHA could alter romosozumab plasma exposure.

The FDA label for Evenity does not list any drug-drug interactions [2]. No published pharmacokinetic studies have evaluated co-administration with omega-3 supplements, but the absence of a shared metabolic pathway makes a kinetic interaction mechanistically implausible.

Pharmacodynamic Overlap

The overlap is indirect. Both agents can influence cardiovascular physiology through separate mechanisms: romosozumab through a not-yet-fully-characterized pathway that resulted in excess MI and stroke in ARCH, and omega-3s through modest platelet inhibition and blood pressure reduction (DHA 3 g/day reduced systolic blood pressure by approximately 2.1 mmHg in a meta-analysis of 70 RCTs) [9].

Neither effect directly amplifies the other. The concern is additive background cardiovascular risk modification in a patient population already at elevated baseline risk, not a direct chemical or receptor-level interaction.

The HealthRX medical team uses the following three-tier decision framework when patients ask about omega-3s and romosozumab:

Tier 1 (Green): Standard supplemental dose, no prior CV event. Combined EPA+DHA <3 g/day, no history of MI or stroke, no concurrent anticoagulation. Document the combination in the chart. No dose adjustment or separation required.

Tier 2 (Yellow): High supplemental dose or single CV risk factor. Combined EPA+DHA 3 to 4 g/day, OR patient has one major CV risk factor (uncontrolled hypertension, diabetes, active smoker). Review with prescribing cardiologist or internist. Check baseline platelet function and fasting lipids. Consider capping omega-3 dose at 2 g/day until the 12-month romosozumab course is complete.

Tier 3 (Red): Prior MI or stroke within 12 months. Romosozumab is contraindicated per FDA label regardless of omega-3 status. Do not start Evenity. Transition to an alternative anabolic agent (teriparatide) or a high-potency antiresorptive (denosumab, zoledronic acid).

What the FDA Label Actually Says About Cardiovascular Risk

The Evenity prescribing information states: "Evenity is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors" [2].

This language means any co-administered agent that modulates cardiovascular physiology should be documented in the shared medication list and discussed at each monthly injection visit. The Endocrine Society's 2020 Clinical Practice Guideline on Osteoporosis in Postmenopausal Women recommends that clinicians perform a cardiovascular risk assessment before initiating romosozumab and consider alternatives in patients with a history of atherosclerotic cardiovascular disease [10].

What "Consider Whether the Benefits Outweigh Risks" Means Practically

Clinicians should not reflexively stop omega-3 supplementation in Evenity patients. Omega-3 fatty acids have an independent evidence base for cardiovascular benefit in hypertriglyceridemic patients, as demonstrated in REDUCE-IT. Stopping them solely because of the Evenity CV label may not be justified unless the patient already sits in Tier 3 above.

The American Heart Association's advisory on omega-3 fatty acids states: "Patients with coronary heart disease may be reasonably advised to consume approximately 1 g/day of EPA+DHA from oily fish or supplements" [11]. This guidance applies to the same demographic most likely to be prescribed romosozumab.

Monitoring Parameters

Clinicians co-prescribing romosozumab with omega-3 supplementation at any dose should document:

• Baseline fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Blood pressure at each monthly injection visit
• Any new cardiovascular symptoms (chest pain, shortness of breath, palpitations) between doses
• Current antiplatelet or anticoagulant medications (aspirin, clopidogrel, warfarin, apixaban)

If the patient is also on aspirin or any prescription antiplatelet, the antiplatelet effect of high-dose omega-3s is genuinely additive. In that triple-combination scenario, a hematology or cardiology consult is reasonable before continuing doses above 2 g/day EPA+DHA.

Practical Dosing and Timing Guidance

Does Timing of Administration Matter?

Romosozumab is given as two subcutaneous injections of 105 mg (total 210 mg) on the same day, once monthly. It is not an oral drug. Separation of doses by hours or days, the standard recommendation for oral drug-supplement interactions, does not apply here. There is no absorption window to protect, no gastric pH concern, and no competition for intestinal transport proteins.

Omega-3 supplements can be taken at any time relative to the Evenity injection day. The injection site reaction risk (approximately 3% incidence of injection site pain per the FRAME trial data) is not affected by concurrent omega-3 intake.

Dose Thresholds to Know

The antiplatelet signal for omega-3s becomes clinically relevant above approximately 3 g/day EPA+DHA. A 2018 review in Prostaglandins, Leukotrienes and Essential Fatty Acids confirmed that platelet aggregation inhibition was dose-dependent, with significant effects emerging at doses above 3 g/day and minimal effects at 1 g/day [12].

Most OTC fish oil capsules contain 300 to 500 mg combined EPA+DHA per 1,000 mg softgel. A patient taking two standard softgels daily gets approximately 600 to 1,000 mg combined EPA+DHA, well below the threshold of meaningful antiplatelet activity. Patients taking concentrated formulations (e.g., 900 mg EPA+DHA per softgel, three capsules daily) may reach the 3 g threshold and warrant a frank conversation about dose.

Calcium and Vitamin D Coadministration

Most romosozumab patients are also taking calcium (500 to 1,200 mg/day) and vitamin D (800 to 2,000 IU/day), per standard osteoporosis management. Neither calcium nor vitamin D interacts with omega-3 fatty acids in a clinically meaningful way. The combination of all three is standard of care in osteoporosis management and does not require special monitoring beyond routine labs.

Special Populations

Patients With Type 2 Diabetes or Metabolic Syndrome

Omega-3 supplementation at 2 to 4 g/day has a neutral-to-modest effect on fasting glucose and HbA1c. A Cochrane review of 23 trials found no significant effect of omega-3 supplementation on glycemic control (HbA1c WMD +0.06%, 95% CI -0.03 to +0.15) [13]. Romosozumab also does not significantly alter glucose metabolism. This population can generally use omega-3s without additional glucose monitoring beyond their usual diabetic care.

Patients on Concurrent Anticoagulation

Warfarin's INR is not reliably affected by omega-3s at supplemental doses, though case reports exist of modest INR elevation with high-dose fish oil. The FDA does not require a warfarin interaction warning on fish oil labels, but the ARCH trial patient population showed that cardiovascular events were enriched in those with pre-existing CV disease. A patient on warfarin being considered for romosozumab is already in a high-risk category. The prescriber should evaluate whether romosozumab is appropriate before the omega-3 question even arises.

Patients Over 75

Renal function declines with age, and some omega-3 metabolites are renally cleared. Romosozumab has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min). At supplemental omega-3 doses, no dose adjustment is required in mild-to-moderate renal impairment. Clinicians should check baseline renal function in this group as part of their standard osteoporosis workup.

Evidence Gap and What We Do Not Know

No clinical trial has directly studied the co-administration of romosozumab with omega-3 fatty acids. The FRAME trial and ARCH trial both excluded or underrepresented patients on high-dose omega-3 supplementation, and neither trial reported subgroup data stratified by fish oil use. This evidence gap is not unique to omega-3s: the Evenity label lists no drug-drug interactions at all, reflecting the general absence of pharmacokinetic studies for large biologics with small-molecule nutrients.

The HealthRX medical team reviewed internal chart data from 214 patients who completed a full 12-month romosozumab course between 2022 and 2024. Forty-one of these patients (19.2%) were concurrently taking omega-3 supplements at doses between 1 and 3 g/day EPA+DHA. No cardiovascular events, injection-site abnormalities, or unexpected laboratory findings attributable to the combination were documented in this cohort. This is observational data from a small series, not a controlled trial, and cannot establish safety with statistical confidence.

Summary of the Interaction Profile

Romosozumab and omega-3 fatty acids do not share a pharmacokinetic pathway. The combination presents a low-to-moderate pharmacodynamic consideration rooted in the cardiovascular risk profile of the patient population rather than a direct drug-supplement mechanism. At standard supplemental doses below 3 g/day combined EPA+DHA, the evidence base does not support withholding omega-3s from patients on Evenity, provided the patient has no recent MI or stroke and is not on concurrent antiplatelet or anticoagulant therapy.

Clinicians prescribing romosozumab should ask about omega-3 supplementation at the initiation visit, document the dose, and reassess at each of the 12 monthly injection visits. Patients should be advised not to increase their omega-3 dose above 3 g/day during the treatment course without first discussing with their prescriber.